ASCO Annual Meeting

Patient Advocacy at ASCO 2022

July 22nd 2022

This year, I returned to the American Society of Clinical Oncology meeting, where I heard about the latest advancements in cancer care, as well as met with fellow patients and advocates.

Time-Limited Venclexta Regimens Outperform Chemoimmunotherapy in CLL

June 13th 2022

Treatment with Venclexta plus Gazyva, with or without Imbruvica, led to better outcomes than chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Brukinsa Continues to Outperform Imbruvica for MYD88-Mutant Waldenström Macroglobulinemia

June 10th 2022

Brukinsa, which was approved in September 2021, resulted in better ouctomes for certain patients with with Waldenström macroglobulinemia, according to the ASPEN clinical trial.

Addition of Stem Cell Transplant Boosts Outcomes for Common Myeloma Regimen

June 10th 2022

Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant.

Pre- and Post-Surgical Jakafi Plus Chemo Shows Potential in Advanced Ovarian Cancer

June 9th 2022

The use of Jakafi plus chemotherapy shows promise in the pre- and post-surgical treatment settings for patients with stage 3 and 4 ovarian cancer, warranting further study of the combination.

Keytruda Demonstrates Significant Improvement for Some Patients with Melanoma

June 9th 2022

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo.

Durable Responses Continue with Keytruda Plus Chemoradiation in Previously Untreated Non-Small Cell Lung Cancer

June 8th 2022

After more than two years of follow-up, patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from treatment with Keytruda and chemoradiation.

Jemperli Eliminated All Signs of Rectal Cancer in Small Clinical Trial, Warranting Further Research

June 8th 2022

One-hundred percent of patients with stage 2/3 mismatch repair-deficient rectal cancer had their disease disappear after treatment with Jermperli, though more research and longer follow-up is needed.

Exkivity Delivers Minimal Benefit to Patients with Non-Small Cell Lung Cancer and Brain Metastases

June 8th 2022

Although ineffective in patients with non-small cell lung cancer and brain metastases at diagnosis, treatment with Exkivity may benefit patients with EGFR exon 20 insertion-positive metastatic disease.

Ifosfamide Induces ‘Subtle’ Survival Improvement Over Hycamtin-Cyclophosphamide Combo in Ewing Sarcoma

June 7th 2022

The use of the chemotherapy ifosfamide was associated with small improvements in survival outcomes in a group of patients with relapsed/refractory Ewing sarcoma, a rare type of bone or soft tissue cancer.

Enhertu Fulfills ‘Big Unmet Need’ for Patients with HER2-Low Metastatic Breast Cancer

June 7th 2022

The findings of the study show that Enhertu should be a new standard of care for patients with HER2-low metastatic breast cancer, according to an expert at Memorial Sloan Kettering Cancer Center.

Adding Darzalex to Popular Multiple Myeloma Treatment Regimen May Lead to Durable Responses

June 7th 2022

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Addition of Tiragolumab to Tecentriq-Chemo Combo Fails to Boost Outcomes in Small Cell Lung Cancer

June 6th 2022

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Keytruda-Cyramza Combo Bests Standard-of-Care Therapies in Previously Treated Non-Small Cell Lung Cancer

June 6th 2022

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

Early Study Findings Show Novel Drug Elicits Promising Results in Metastatic Breast Cancers

June 6th 2022

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

SOT101 With or Without Keytruda Shows Promise, Safety in Treating Advanced Solid Tumors

June 6th 2022

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Calquence-Based Regimens Continue to Elicit Better Results Than Gazyva Plus Chemotherapy in Untreated Chronic Lymphocytic Leukemia

June 5th 2022

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Trodelvy Reduces Risk of Disease Progression in Certain Patients With Metastatic Breast Cancer

June 5th 2022

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Lenvima Plus Keytruda May Become Next Standard-of-Care Treatment Option for Advanced Kidney Cancer

June 5th 2022

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Adcetris Plus Chemo ‘Potentially Cured’ Some Patients With Hodgkin Lymphoma

June 5th 2022

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Tibsovo Plus Vidaza Is Beneficial for Patients With IDH1-Mutant Acute Myeloid Leukemia

June 4th 2022

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

Cabometyx Failed to Improve Survival in Advanced Bladder Cancer

June 4th 2022

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

New Drug May Mitigate Incidence, Severity of Chemotherapy-Related Oral Mucositis in Patients With Head and Neck Cancer

June 4th 2022

Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.

Treatment With Vonjo May Elicit Fewer Side Effects Than Other Available Therapies in Myelofibrosis, a Rare Type of Blood Cancer

June 4th 2022

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Adagrasib Shows Promise in Difficult-to-Treat Lung Cancer Subset

June 4th 2022

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

Chemotherapy Plus Nimotuzumab Improves Survival in Certain Patients with Advanced Pancreatic Cancer

June 3rd 2022

The addition of nimotuzumab to a treatment regimen of the chemotherapy gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer.

‘A New Benchmark’ Treatment Option for Older Patients with Mantle Cell Lymphoma

June 3rd 2022

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

Hispanic Children With Neuroblastoma Have Poorer Trial Outcomes: Describing Disparities Is ‘Simply Not Enough’

June 1st 2022

Research showed that Hispanic children with neuroblastoma who are participating on clinical trials tended to have worse survival outcomes than others.

More Effort is Needed to Inform Black Patients With Metastatic Breast Cancer to Increase Clinical Trial Participation

May 31st 2022

A small percentage of patients with metastatic breast cancer participating in clinical trials in the U.S. are Black, which, according to a patient living with the disease is a huge concern since it doesn’t represent the general population.

Telehealth Use for Cancer Care Surged During COVID-19, But Inequalities Remain

May 27th 2022

An analysis of more than 25,000 patients with one of the more than 20 common cancers identified that even though telehealth use for cancer care increased during the COVID-19 pandemic, certain people were less likely to benefit from the easy access to care.

NEXT PAGE
PREVIOUS PAGE